A phase II trial was performed to assess the antitumor activity and toxicity of estramustine in combination with vinblastine and mitomycin-C in 46 consecutive patients with androgen independent prostate cancer. All patients presented with disease progression following castrate serum testosterone levels and were treated for six consecutive weeks with three daily 140 mg doses of oral estramustine, vinblastine at 5 mgam 2 weekly by intravenous bolus and mitomycin-C at 15 mgam 2 every six weeks by intravenous bolus. Prostate speci®c antigen levels decreased by greater than 50% from baseline in 16 (41%; 95% CI 25 ± 58%) and normalized in 11 (28%; 95% CI 14 ± 45%) of 39 evaluable patients. Patients who demonstrated a greater than 50% reduction in PSA had a longer delay in time to disease progression. Non-hematologic toxicity was mild, predominately gastrointestinal. Hematologic toxicity was apparent in ®ve patients with Grade III granulocytopenia and in 21 patients with Grade IV granulocytopenia of 43 evaluable patients for toxicity. Three patients were admitted to the hospital for neutropenic fever. Eight patients had Grade III thrombocytopenia, four patients had Grade IV thrombocytopenia, no bleeding occurred. Estramustine in combination with vinblastine and mitomycin-C is an active regimen. The non-hematologic toxicity was tolerable, while the hematologic toxicity required individual dosage reduction. The combination and the clinical signi®cance of the decline in the PSA warrants further investigation.
Introduction
Androgen-independent prostate cancer (AIPCa) is a particularly lethal tumor with a short median survival. 1, 2 It is the most commonly detected malignancy in males, with 350 000 estimated cases in the United States for 1997. 1 It is ranked as the second leading cause of male cancer death and is associated with 41 000 estimated deaths for 1997. 1 Despite the increasing reports of chemotherapy trials for AIPCa, general pessimism remains about the promise of aggressive chemotherapy. 3 ± 11 The traditional schedules of monthly chemotherapy with a combination of cytotoxic chemotherapy agents appear not to have convincingly increased the response rate over sequential single agent chemotherapy. 3 ± 11 Response rates have ranged from less than 10% to up to 50% in the various series using similar drugs. In addition, older patients with advanced prostate carcinoma (PCa) do not tolerate such combination chemotherapy regimens.
Although chemotherapy for AIPCa has proved unsatisfactory, innovative therapeutic approaches are nevertheless justi®ed. We have been engaged in designing a drug regimen that would be safe and effective against advanced progressive AIPCa. Among the possible choices for this regimen is vinblastine, a well known microtubular inhibitor. Dexeus et al 12 reported that continuous infusion of vinblastine at 1.5 mgam 2 daily for ®ve days resulted in a 21% response rate in patients with AIPCa. Of 39 patients, eight patients, (two with visceral metastasis, one with nodal metastasis and ®ve with osseous metastasis) achieved an objective response by clinical criteria. The median duration of this response was 28 weeks. We plan to give the drug in an intravenous bolus schedule, though there have been no published reports of this schedule's effectiveness against AIPCa. For estramustine, the second drug under consideration, the antitumor activity in androgen independent disease is disputed and appears to be minimal. 13, 14 However, recent preclinical data suggests that estramustine has a unique pattern of antitumor activity, a mechanism of action based on microtubular inhibition. 15 ± 20 In vitro tests suggest that the combined effect of estramustine and vinblastine is synergistic, producing a complete disassembly of the cytoplasmic microtubules, a prostatic cell line (DU145) being the most sensitive. 21 Combining cytotoxic chemotherapy with the two agents, estramustine and vinblastine has been proposed to be an effective treatment regimen for patients with AIPCa. 22 ± 24 The potential clinical value of this combination regimen is enhanced by similar results achieved by other investigators using the same combination in different doses and schedules (Table 1 ). The two basic differences are that other investigators (1) emphasize the dose of estramustine, as opposed to our schedule, which emphasizes the dose of vinblastine; and (2) had a two week break in their schedule designs compared to our design with no break. A recent completed clinical trial at the M.D. Anderson Cancer Center comparing single agent intravenous bolus vinblastine to the combination supports the two agents with their novel mechanism of action (unpublished data). 25 Our experience with the treatment of metastatic PCa with cytotoxic chemotherapy suggests that mitomycin-C is an effective agent in achieving responses in this tumor. The ability of mitomycin-C to achieve responses has been con®rmed by multiple single agent trials. 26 ± 28 Based on the preclinical data, the phase II trials that have been conducted with the combination estramustine and vinblastine, and that mitomycin-C is an active agent in AIPCa, we initiated a phase II trial for patients with histologically con®rmed advanced adenocarcinoma of the prostate that exhibited androgen independent growth. Changes in the level of serum biomarker prostatic speci®c antigen (PSA) were used to determine evidence of therapeutic activity. 29, 30 
Materials and methods
Patients continued primary hormonal therapy that induced castrate testosterone levels (orchiectomy or luteinizing hormone releasing hormone (LHRH) antagonist). Patients were referred for the management of progressive AIPCa between February of 1991 and October of 1992. Those with histologic proof of adenocarcinoma of the prostate with the exclusion of the small cell variant, and documented evidence of tumor progression within six months of placement on protocol were considered for the study. Progression was de®ned as the development of new sites of metastasis, objective evidence of progression at previous sites of metastasis, or rising serum PSA on two consecutive determinations in the presence of castrate levels of serum testosterone (`50 ngadl).
All patients gave informed written consent to participate in this study, which was approved by the Institutional Review Board of the University of Texas M.D. Anderson Cancer Center before study entry. The pretreatment evaluation included: a complete history and physical examination, complete blood count, platelet count, electrolytes, biochemical pro®le, PSA, and testosterone level. Also included were a urine analysis, chest X-ray, bone scan, and computerized tomography of the abdomen and pelvis.
PSA was included as a reliable serum tumor marker of metastatic disease as it has been reported to have prognostic signi®cance. 29, 30 While tumor responses are often dif®cult to assess, PSA levels can be determined without dif®culty. Investigators have shown that changes in the PSA correlate with disease regression in patients treated with androgen ablation and in symptomatic patients with AIPCa who demonstrated subjective improvement. 29, 30 All patients had acinar adenocarcinoma, and for initial therapy, all had received hormonal therapy. In addition, one patient received prior chemotherapy, and 30 patients received prior radiation therapy. The median patient age was 67 y (range 50 ± 78 y), and the median Zubrod Performance Status was distributed as follows: (Zubrod 0, 13 patients; Zubrod 1, 26 patients; Zubrod 2, 4 patients).
Patients were divided into categories as determined by the staging system used at The University of Texas M.D. And-erson Cancer Center for metastatic PCa, a staging system found to be reproducible in sequential trials. 7 Patients were strati®ed by volume of osseous involvement and the presence of visceral metastasis: osseous (O1), axial skeleton; osseous (O2), axial skeleton plus diaphyseal and distal extremity involvement; visceral I (V1), parenchymal lung metastasis; and visceral II (V2), visceral other than lung, usually liver, brain and mediastinum. Patients who otherwise would have been classi®ed in the O1 or V1 categories but had bone marrow failure attributed to tumor in®ltration of the marrow cavity or renal failure (serum creatinine b 2 mgadL) were placed in their respective stage II category. Nodal metastasis was thought to be present in all patients prior to involvement of the skeleton or viscera and so were not added to the staging system unless the mediastinum or supraclavicular area was involved. Patients who had osseous metastasis and mediastinal disease were placed in the V2 category. Patients with nodule metastasis as the only manifestation of recurrent AIPCa were included in the O1 category. The distribution of patients by stage was: osseous I, 9 patients; osseous II, 20 patients; VI, 3 patients, and VII, 5 patients. Four patients had advanced local disease. All but two patients had abnormal baseline PSAs ranging from 5 ± 5415 gaml (median 93).
Evaluation during therapy consisted of weekly complete blood and platelet counts. Biochemical pro®le and electrolytes were performed at every course or as frequently as needed to further de®ne toxicity. An interim history and physical examination with PSA were recorded every 42 d. Radiographic studies of known metastasis were performed every 84 d.
Response criteria
The response criteria employed throughout our study required an improvement of all parameters used. For visceral or nodal disease response, a complete response (CR) required the complete disappearance of all radiographic evidence of disease, persistent for at least four weeks. A partial response (PR) required a 50% or greater reduction in the sum of two perpendicular diameters of measured lesions, persisting for at least four weeks. To be considered responders the patients were required to have a 50% reduction in their elevated PSA for a minimum of two consecutive months. If visceral or nodal metastasis were present, a greater than 50% reduction in the sum of two perpendicular diameters was required. No clinical deterioration attributable to tumor growth or new metastatic sites could develop. Patients whose tumors could be measured had appropriate radiologic studies performed at 12 week intervals.
Therapy
All treatment was administered on an outpatient basis. A course was de®ned as six consecutive weeks, and there was no rest between each course. The starting dose level of the combination included estramustine at 420 mg taken orally in three divided doses daily for all 42 d and vinblastine at 5 mgam 2 per week as an intravenous bolus injection and the mitomycin-C was given at 15 mga m 2 on day 1 as an intravenous bolus injection every six weeks. Patients were given antiemetics for as needed use. Decadron was not a prescribed antiemetic. Patients were instructed not to take the estramustine with dairy products, antacids, carafate, or H2 antagonists in order to avoid impaired absorption. 16 Vinblastine and mitomycin-C were held when an absolute granulocyte count of less than 900 cellsamm 3 or platelet count of less than 50 000 cells mm 3 was revealed or Grade III or IV nonhematologic toxicity, speci®cally painful sensory neuropathy or motor neuropathy, ileus requiring nasal gastric tube placement, constipation requiring hospitalization, evidence of hemolysis, azotemia, or interstitial pneumonitis was recognized. The vinblastine and mitomycin-C were held pending hematologic recovery de®ned as granulocytes of 1500 cells per mm 3 or greater and platelets of more than 100 000 cells per mm 3 and with a complete recovery of non-hematologic toxicity. Upon the recovery from the respective toxicity, a dose reduction of the vinblastine by 1 mgam 2 to 4 mgam 2 was initiated and a second dose reduction of vinblastine to 3 mgam 2 could be initiated based on similar parameters. The mitomycin-C dose was reduced to 12 mgam 2 upon reinitiation of therapy and a second dose reduction of mitomycin-C to 10 mgam 2 could be initiated based on similar parameters. Therapy was continued for at least 42 d unless there was rapid progression of disease and for at least 84 d if no change in disease was noted and intolerable Grade III or IV toxicity was not seen. Responding patients continued until disease progressed. Patients with a minimum response or no change in the disease status continued on therapy at the discretion of the study chairperson until disease clearly progressed.
Results
We registered 46 men with progressive AIPCa for this phase II trial. Of these 46 patients, 41 patients were evaluable for response and toxicity, and two patients were evaluable for toxicity only; three patients were inevaluable. Of the two patients who were considered evaluable for toxicity only, this was secondary to receiving less than 84 d of therapy due to hematologic toxicity in one patient and a deep venous thrombosis in the other patient, both opting for supportive care only. The three inevaluable patients were lost for follow-up. Of the 41 evaluable patients, 16 patients (41%; 95% CI 25 ± 58%) had a greater than 50% reduction in serum PSA and 11 (28%; 95% CI (14 ± 45%) patients normalized their serum PSA for at least two consecutive months (Table 2 breaks down the PSA outcomes based on MDA-staging culture). The in¯uence of the serum PSA on time to progression is illustrated in Table 3 . The 27 patients (69%) who demonstrated a greater than 50% reduction or normalization in their serum PSA had a longer delay in time to progression compared with those with a 50% or less reduction but this was not statistically signi®cant.
In the 25 patients with measurable soft tissue involvement that could be evaluated with standard response criteria, partial responses were observed, seven nodal metastatic sites (periaortic, pelvic) and three in the liver. Seven of the responses were associated with a more than 50% reduction in serum PSA. Of the two patients with a normal PSA at baseline, one had a partial response in measurable disease while the other progressed.
The minimum number of cycles given was 3 with a range of 1 ± 5. Fifteen patients were reduced to dose level one (5 mgam 2 of vinblastine, 12 mgam 2 of mitomycin), additionally 10 patients were further reduced to 10 mgam 2 of mitomycin-C and 3 mgam 2 of vinblastine. We correlated PSA response to prior¯utamide therapy. Nineteen (70%) of 27 assessable patients with previous utamide therapy had responses, compared with 7 (50%) of 14 patients without previous¯utamide exposure. Timing of the¯utamide withdrawal was not adequately controlled. Removal did not in¯uence the response.
Toxicity
The combination of estramustine with vinblastine and mitomycin-C was easily administered in an outpatient setting. The hematologic and non-hematologic toxicities of the combination are summarized in Table 4 . The non-hematologic toxicity was mild, predominantly, gastrointestinal. The nausea and emesis were related to the oral estramustine and usually controllable with an oral antiemetic. The neurologic toxicity (constipation, parathesias) associated with vinblastine was usually mild. Hematologic toxicity was found in ®ve patients with Grade III granulocytopenia and 21 patients with Grade IV granulocytopenia. Three patients were admitted to the hospital with neutropenic fever. Eight patients had Grade III thrombocytopenia, while four patients exhibited Grade IV thrombocytopenia. No bleeding occurred. Fourteen patients had Grade III or IV anaemia requiring packed blood cell transfusions. The incidence of hematologic toxicity decreased following a reduction in the vinblastine dose from 5 mgam 2 to 4 mgam 2 and the mitomycin-C dose from 15 mgam 2 to 12 mgam 2 .
Discussion
This present study demonstrates that the combination of estramustine, vinblastine and mitomycin-C has activity against progressive AIPCa. Of the 41 evaluable patients, 39 with an elevated PSA the initiation of therapy, 69% had a greater than 50% reduction in the serum PSA levels; in 7 (30%) of 23 patients, the PSA reduction correlated with a partial response. The antitumor activity between single agent and multi-agent trials should be interpreted, this the heterogeneous behavior of metastatic PCA has complicated the interpretation of the results. In addition, fully measurable disease with dominant osseous spread has further complicated the interpretation of the results. The clinical characteristics of the patients we presented are different between single-agent and multi-agent trials and furthermore, PSA was not available at the time of the single-agent vinblastine trial, single agent mitomycin-C trials or in the majority of the single-agent estramustine trials. There was little difference in response between the substages of patients with progressive androgen-independent disease. These four categories were determined by the metastatic pattern and the extent of the involvement in each of the metastatic sites. Historically, chemotherapy results in each of these four stages have differed signi®-cantly. 11 Improved chemotherapy responses and prolonged survival among patients with small tumor burden is seen in most chemotherapy trials. Among patients with osseous metastases those categorized as OI with axial skeletal involvement typically have a higher response rate than those categorized as OII. Similarly, in patients categorized as VI and VII nonosseous visceral involvement, the expected lower response rate and poor survival for those with more burden has been reported. 7 Because of the number of patients in each of the prognostic categories is small, it is dif®cult to conclude any difference.
The toxicity of this three-drug combination is acceptable. The nonhematologic side effects were mild. The nausea and emesis, which were attributed to the estamustine, were controlled with oral antiemetic agents. The neurologic sequela (constipation and peripheral neuropathy) were attributed to the vinblastine and controlled with dose reductions of vinblastine. The hematologic side effects were predominately granulocytopenia. In review Treatment of androgen independent prostate cancer RJ Amato et al of the absence of mucositis, only three of these patients required admission to the hospital for neutropenic fever. Thrombocytopenia occurred less frequently, with no bleeding episodes. Individual dose reductions in both the vinblastine and mitomycin-C were necessary to reduce the myelosuppression in subsequent courses of chemotherapy delivered. Our data imply that the chronic schedule of administering these agents with different toxicity spectra enabled us to combine successfully the optimal doses of each individual agent. The delivery of chronic therapy as in this schedule is particularly suitable for the treatment of patients with AIPCa. These patients are typically elderly, the high-dose intermittent therapy has resulted in severe myelosuppression with multiple infectious complications. By using a chronic schedule of chemotherapy, severe myelosuppression can be avoided, and yet signi®cant total dose can be delivered, therefore, these chronic approaches may have a signi®cant therapeutic advantage.
Conclusions
The potential clinical value of this combination needs to be further evaluated. This chemotherapy regimen can be designed to further reduce the myelosuppression by providing a two-week rest period, six weeks of active therapy and two weeks off as our current trials allow. In addition, reducing the initial doses of mitomycin-C to 12 mgam 2 the most common dose given to this patient population should further reduce the myelosuppression. The chemotherapy regimen then can be distinguished from traditional courses and schedules of cytotoxic chemotherapy by two factors, the incorporation of estramustine and the chronic schedule. The chronic schedule being suitable for prostatic carcinoma, a tumor with a low proliferation rate, and provide signi®cant dose with more potential control of the morbidity for this patient population.
Based on these ®ndings, we believe that the combination of estramustine, vinblastine and mitomycine-C should be more thoroughly investigated in the treatment of AIPCa.
